Nicole Sadek, ICIJ

Nicole Sadek is an investigative reporter for ICIJ. Previously, she was an investigative data reporter at Bloomberg Law. Her work has appeared in The Washington Post, ProPublica, Bloomberg News and other publications. Nicole is the winner of the 2025 Livingston Award for International Reporting.

Nicole holds a bachelor's degree in international studies and creative writing from Emory University and a master's degree in investigative journalism from Arizona State University. She first joined ICIJ in 2022 as an editorial fellow as part of the Scripps Howard Foundation's Roy W. Howard Fellowship program.

Investigations

Damascus Dossier

China Targets

Caspian Cabals

Shadow Diplomats

Durga as the Slayer of the Buffalo Demon

Hidden Treasures

The Uber Files

Russia Archive

The Ericsson List

Stories by Nicole Sadek

Tunisian authorities threaten to dissolve the parent company of ICIJ partner Inkyfada

The move follows years of legal harassment by government agencies and a wider, escalating crackdown on the Tunisian press.

May 07, 2026

‘Escalating efforts’: A year after China Targets, Beijing’s global campaign against dissenters continues

In 2025, China was the most prolific perpetrator of transnational repression, a new Freedom House report found.

Apr 28, 2026

Photo of a group of protesters wearing flags and holding signs, including one that reads Bow to China Lose Forever.

‘Unacceptable’: Lawmakers react to revelations from ICIJ’s Cancer Calculus investigation

In hearings around the world, politicians and experts called for inquiries into inequities surrounding Merck's anti-cancer drug Keytruda.

Apr 23, 2026

SUMMIT, NJ - OCTOBER 2: A Merck flag flies in front of the company's building on October 2, 2013 in Summit, New Jersey. The pharmaceutical company Merck & Co. announced today that it would cut 8,500 jobs and consolidate its real estate in Kenilworth, New Jersey instead of moving its headquarters to Summit as previously planned.

Report: Merck’s blockbuster cancer drug topped $200,000 a year under Trump

Despite the president’s plan to lower prescription medicine costs, the price of many of the most expensive drugs — including several immunotherapy treatments — have continued to rise.